Holen Sie sich die Stockscreener-App
73.34
1.52%
-1.13
Handel nachbörslich:
73.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$74.47
Offen:
$74.68
24-Stunden-Volumen:
1.54M
Relative Volume:
0.98
Marktkapitalisierung:
$35.75B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
37.14
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
-0.42%
1M Leistung:
-15.88%
6M Leistung:
-0.78%
1J Leistung:
-24.24%
1-Tages-Spanne:
$73.21
$74.80
1-Wochen-Bereich:
$73.12
$76.35
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
73.34 | 35.75B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
452.66 | 160.77B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.51 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
41.36 | 33.57B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
220.47 | 32.12B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon Inc Stock: Global Leader in Eye Care with Strong Growth Potential for North American Investors - AD HOC NEWS
Alcon announces $81 million expansion in Cabell County, 75 new jobs expected - wowktv.com
Alcon Inc Stock: Global Leader in Eye Care Innovation and Steady Growth Potential for Investors - AD HOC NEWS
Alcon Inc. Stock: A Leader in Eye Care Innovation Driving Steady Growth for North American Investors - AD HOC NEWS
Alcon expansion to create more West Virginia jobs - wowktv.com
Systane Eye Drops: Alcon's Leading Solution for Dry Eye Relief in North America - AD HOC NEWS
Analyst Upgrade: Is Alcon Inc benefiting from innovation trendsPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
Alcon Inc stock faces uncertainty as Lensar merger collapses, pivots to organic growth strategy - AD HOC NEWS
LENSAR Inc stock plunges as Alcon terminates merger over FTC antitrust block - AD HOC NEWS
LENSAR Inc stock faces prolonged uncertainty as Alcon merger awaits FTC approval amid regulatory del - AD HOC NEWS
LENSAR Inc stock faces uncertainty as Alcon merger awaits final regulatory approval amid pending FTC - AD HOC NEWS
World Council of Optometry and Alcon Introduce Dry Eye Management Map - VisionMonday.com
Alcon Inc stock faces uncertainty as Lensar merger collapses, prompting strategic pivot to core eye - AD HOC NEWS
ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill
BTIG Reiterates 'Buy' Rating for Alcon (ALC) with $92 Price Targ - GuruFocus
Eaton Vance Worldwide Health Sciences Fund's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
US LASIK Treatment Market Set to Witness Rapid Growth Through - openPR.com
Alcon Inc. stock faces steady demand amid eye care sector shifts and portfolio updates - AD HOC NEWS
Is It Time To Reassess Alcon (SWX:ALC) After A 26.9% Share Price Slide? - Yahoo Finance
STAAR Surgical Co stock faces acquisition scrutiny as Alcon deal advances amid analyst caution - AD HOC NEWS
Guidance Update: Should I invest in Alcon Inc before earnings2026 Top Decliners & Comprehensive Market Scan Insights - baoquankhu1.vn
Alcon Inc stock faces pressure amid terminated LENSAR merger and market downturn - AD HOC NEWS
Alcon Inc. stock faces headwinds amid surgical slowdown and tariff risks in eye care sector - AD HOC NEWS
Alcon, LENSAR abandon proposed merger amidst FTC pushback - Ophthalmology Times
Alcon Inc. stock gains momentum as AlphaValue upgrades rating to Buy amid eye care sector resilience - AD HOC NEWS
Lensar agrees to terminate sale to Alcon - MSN
Systane Eye Drops Lead Alcon's Shift to Organic Growth After Lensar Deal Collapse - AD HOC NEWS
Alcon and Lensar terminate proposed merger after FTC pressure - Eyes On Eyecare
EV Market: Can Alcon Inc outperform in the next rally2026 Price Targets & Long-Term Growth Stock Strategies - baoquankhu1.vn
Alcon And LENSAR: Why The Broken Merger Creates Two Different Buy Cases (NYSE:ALC) - Seeking Alpha
Alcon and Lensar Agree to Terminate Merger Agreement - VisionMonday.com
BTIG upgrades Lensar stock rating to buy after Alcon deal ends - Investing.com Canada
ACQUISITIONS & MERGERS NEWS: FTC successfully blocks Alcon-LENSAR merger in cataract surgery laser market - VitalLaw.com
BTIG upgrades Lensar stock rating to buy after Alcon deal ends By Investing.com - Investing.com South Africa
Alcon Drops $430M Lensar Deal Under Pressure From FTC - Law360
Alcon abandons effort to purchase LENSAR after FTC scrutiny - MedTech Dive
LENSAR Terminates Merger Agreement with Alcon Following FTC Challenge, Retains $10M Deposit and Announces Strategic Update - Minichart
Lensar Share Slide on Terminated Merger Deal With Alcon - marketscreener.com
Alcon, LENSAR terminate merger agreement after US FTC opposition - MLex
Alcon, LENSAR Halt Merger Deal Amid FTC Scrutiny - Medical Product Outsourcing
US FTC stops proposed merger of Alcon, LENSAR - MLex
US FTC Says It Stops Proposed Merger Of Cataract-Surgery Device Makers Lensar And Alcon - TradingView
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Ends Alcon Merger, Plans Strategic Update - TipRanks
Lensar and Alcon Sign Termination Agreement; Lensar Retains $10 Million Deposit - TradingView
LENSAR (NASDAQ: LNSR) terminates Alcon merger, retains $10M and plans strategy update - Stock Titan
Alcon Inc stock terminates Lensar merger amid US regulatory hurdles, shifts focus to core growth - AD HOC NEWS
Lensar to terminate Alcon merger agreement - Yahoo Finance
Switzerland: Alcon and Lensar agree to terminate merger agreement - Investors in Healthcare
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):